BAYER TO PAY $9.6 BILLION TO SETTLE U.S. ROUNDUP SUITS

Bayer AG, the German company that owns the Roundup brand of glyphosate weed killer, will pay $9.6 billion to settle about 95,000 U.S. lawsuits alleging that the herbicide causes non-Hodgkins lymphoma, a form of cancer.

Roundup was developed by American chemical giant Monsanto, which Bayer bought for $63 billion in 2018.

TRENDPOST: Remember the big Climate Change trend, and how so many were so concerned about its implications before COVID Hysteria took center stage?

As Gerald Celente said during the height of it, “Climate Change, forget about it.
With all the poisons, chemicals, pesticides, GMO, they are injecting into our food and the trillions of tons they are injecting into the earth, water and air, we’ll be
dead before the climate changes.”

Source:

Trends Journal

The HighWire with Del Bigtree

Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. The content in my videos and on the WORDPRESS – WORDPRESS channel are provided for informational purposes only. Use the information found in these videos as a starting point for conducting your own research and conduct your own due diligence BEFORE making any significant investing decisions. WORDPRESS assumes all information to be truthful and reliable; however, I cannot and do not warrant or guarantee the accuracy of this information. Thank you!

Henrietta Lacks: At Your Cervix

This video should go ‘viral’. Every woman in the world should view this.

Vaccines are biological weapons.  Do not submit to be killed by them.  Stay the F$$$ out from them and if you are near them call Homeland Security and the EPA for a biohazard cleanup.

All other videos on the topic of Henrietta Lacks make it appear as if her cancerous cervical cells are the greatest thing for medicine and humanity in general, and while i understand, from a research perspective, how beneficial cells like this would be. i am curious how anyone “benefits” from receiving cancer cells that never die in vaccines. Since we have had vaccines, cancer deaths have skyrocketed, as well as autism, diabetes and a slue of other debilitating diseases.

Source:

vaccinefraud

 Patrick Jordan @ http://www.VaccineFraud.com

 

Fair Use Notice: Images/logos/graphics on this page contains some copyrighted material whose use has not been authorized by the copyright owners. We believe that this not-for-profit, educational, and/or criticism or commentary use on the Web constitutes a fair use of the copyrighted material (as provided for in section 107 of the US Copyright Law).

FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer

FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer

The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.

Lung cancer is the leading cause of cancer-related death among men and women in the U.S. and, though more common in men, the number of deaths from lung cancer in women is increasing. According to the National Cancer Institute, an estimated 221,200 Americans will be diagnosed with lung cancer, and 158,040 will die from the disease this year. NSCLC is the most common type of lung cancer. Mutations in the EGFR gene are present in about 10 percent of NSCLC tumors.

Iressa is a kinase inhibitor that blocks proteins that promote the development of cancerous cells with certain EGFR mutations. It is intended for the treatment of patients whose tumors express the most common types of EGFR mutations in NSCLC (exon 19 deletions or exon 21 L858R substitution gene mutations). The therascreen EGFR RGQ PCR Kit was approved as a companion diagnostic test to identify patients with tumors having the EGFR gene mutations in order to determine which patients would be appropriate for treatment with Iressa.

The FDA granted Iressa orphan product designation for the treatment of EGFR mutation-positive metastatic NSCLC. Orphan product designation is given to drugs intended to treat rare diseases, which provides financial incentives – like tax credits, user fee waivers, and eligibility for market exclusivity – to promote their development.

The efficacy and safety of Iressa for this use was demonstrated in a multi-center, single-arm clinical trial of 106 patients with previously untreated, EGFR mutation-positive metastatic NSCLC. The study’s primary endpoint was objective response rate, or the percentage of patients who experienced complete and partial shrinkage or disappearance of the tumors after treatment. Participants received Iressa 250 mg once daily. Results showed that tumors shrank in about 50 percent of patients after treatment and this effect lasted an average of six months. The response rates were similar in patients whether their tumors had EGFR exon 19 deletions or exon 21 L858R substitution mutations.

For more information, please visit: Iressa